|
 |
Prekinis pavadinimas |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Accofil |
Belgija, Didžioji Britanija, Kroatija, Vokietija |
|
Duperan |
Čilė |
|
Filgen |
Argentina, Čilė |
|
Foltran |
Čilė |
|
Granulokine |
Brazilija, Graikija, Italija |
|
Hebervital |
Kolumbija |
|
Inmunef |
Kolumbija, Meksikas |
|
Leucosos |
Kolumbija |
|
Lioplim |
Čilė |
|
Neupogen |
Airija, Australija, Austrija, Belgija, Čilė, Danija, Didžioji Britanija, Egiptas, Ekvadoras, Iranas, Ispanija, Jungtinės Amerikos Valstijos, Jungtiniai Arabų Emyratai, Kanada, Kolumbija, Lenkija, Liuksemburgas, Malaizija, Marokas, Meksikas, Naujojoje Zelandijoje, Norvegija, Olandija, Portugalija, Prancūzija, Saudo Arabija, Slovėnija, Suomija, Švedija, Šveicarija, Turkija, Venesuela, Vokietija |
|
Neutromax |
Argentina |
|
Neutropine |
Argentina |
|
Nivestim |
Belgija, Didžioji Britanija, Norvegija, Olandija, Prancūzija, Vokietija |
|
Ratiograstim |
Austrija, Didžioji Britanija, Švedija, Vokietija |
|
Tevagrastim |
Belgija, Brazilija, Čilė, Didžioji Britanija, Ispanija, Kroatija, Norvegija, Olandija, Švedija, Šveicarija, Vokietija |
|
|
 |
 |
Bibliografija : Filgrastim |
|
|
tipas |
leidinys |
| 99 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 104 |
Žurnalas |
Hall PD, Yui D, Lyons S, Bosso JA.
Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 185-189. |
| 182 |
Žurnalas |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 2269 |
Žurnalas |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 3128 |
Laboratorija |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013 |
| 3249 |
Žurnalas |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3256 |
Žurnalas |
Burnett B, Radic I.
Stability of Hospira filgrastim following changes to thermal and photic storage conditions.
EJHP 2011 ; 17, 5: 49-56. |
| 3474 |
Laboratorija |
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009 |
| 3618 |
Laboratorija |
Filgrastim (Neupogen®) - Summary of Product Characteristics
Amgen 2014 |
| 3828 |
plakatas |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
plakatas |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 4055 |
Žurnalas |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4380 |
Laboratorija |
Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019 |
| 4471 |
Laboratorija |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019 |
| 4521 |
Žurnalas |
Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020 |
| 4650 |
Laboratorija |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
|
|
